Batimastat sodium salt

目录号: GC35470纯度: >98%同义词: (2S,3R)-N-羟基-N'-[(2S)-1-甲基氨基-1-氧代-3-苯基丙-2-基]-3-异丁基-2-(噻吩-2-基硫甲基)丁二酰胺单钠盐,BB-94 sodium salt
A potent broad spectrum inhibitor of MMPs

Batimastat sodium salt
Cas No.: 130464-84-5
规格价格库存数量操作
1mg¥405.00现货
1
5mg¥837.00现货
1
10mg¥1,256.00现货
1

文献被引

本产品暂无引用记录;以下为 GlpBio 产品在 Nature / Cell / Science 等顶刊的客户引用样例
  • Nature cover
    Nature
    641, 529–536 (2025)
  • Nature cover
    Nature
    628, 630–638 (2024)
  • Nature cover
    Nature
    632, 686–694 (2024)
  • Nature cover
    Nature
    618, 1017–1023 (2023)
  • Nature cover
    Nature
    610, 366–372 (2022)
  • Cell cover
    Cell
    187(9):2288-2304 (2024)
  • Cell cover
    Cell
    183(7):1867-1883 (2020)
  • Science cover
    Science
    388(6745) (2025)
  • Science cover
    Science
    387(6739) (2025)
  • Science cover
    Science
    387(6734) (2025)
  • Cell Research cover
    Cell Research
    35, 97–116 (2025)
  • Cell Research cover
    Cell Research
    34, 683–706 (2024)
  • Cell Research cover
    Cell Research
    33, 273–287 (2023)
  • Cell Research cover
    Cell Research
    33, 546–561 (2023)
  • Cell Research cover
    Cell Research
    33, 904–922 (2023)
  • Cell Research cover
    Cell Research
    31, 1291–1307 (2021)

产品描述 Description

Batimastat is a broad spectrum inhibitor of matrix metalloproteinases (MMP), with IC50 values of 1-5 nM for all MMPs tested, including MMP-1, -2, -3, -7, -9, -13, and -14.1,2,3,4 It also potently inhibits TNFα-converting enzyme (IC50 = 14.9 nM).2 Because of its action on MMPs, batimastat has anti-proliferative, anti-invasive, and anti-metastatic actions that are relevant, in particular, to cancer.5 Batimastat less effectively inhibits the processing of the low affinity IgE receptor CD23 (IC50 = 100 nM).6

1.Fray, M.J., Burslem, M.F., and Dickinson, R.P.Selectivity of inhibition of matrix metalloproteases MMP-3 and MMP-2 by succinyl hydroxamates and their carboxylic acid analogues is dependent on P3' group chiralityBioorg. Med. Chem. Lett.11(4)567-570(2001) 2.Fray, M.J., Dickinson, R.P., Huggins, J.P., et al.A potent, selective inhibitor of matrix metalloproteinase-3 for the topical treatment of chronic dermal ulcersJ. Med. Chem.46(16)3514-3525(2003) 3.Sheppard, G.S., Florjancic, A.S., Giesler, J.R., et al.Aryl ketones as novel replacements for the C-terminal amide bond of succinyl hydroxamate MMP inhibitorsBioorg. Med. Chem. Lett.8(22)3251-3256(1998) 4.Yamamoto, M., Tsujishita, H., Hori, N., et al.Inhibition of membrane-type 1 matrix metalloproteinase by hydroxamate inhibitors: An examination of the subsite pocketJ. Med. Chem.41(8)1209-1217(1998) 5.Chaudhary, A.K., Pandya, S., Ghosh, K., et al.Matrix metalloproteinase and its drug targets therapy in solid and hematological malignancies: An overviewMutat. Res.753(1)7-23(2013) 6.Bailey, S., Bolognese, B., Buckle, D.R., et al.Selective inhibition of low affinity IgE receptor (CD23) processingBioorg. Med. Chem. Lett.8(1)29-34(1998)

实验参考方法 Experimental Reference Method

Animal experiment:

Mice[5] Six-weeks-old female BALB/c mice are used. Mice are treated i.p. with Batimastat (BB-94, 50 mg/kg) 1 h before and 24 h post-infection. Batimastat is suspended at 50 mg/mL in DMSO and stored frozen at -20°C. Prior to use, it is diluted 20-fold in phosphate buffered saline (PBS), and 500 μL are injected into animals. Control mice are injected with 500 μL of 5% DMSO in PBS. Animals are sacrificed 48 h after i.c. challenge. Rats[6] Female Sprague-Dawley rats are administered a single physiological dose of E2 (40 μg/kg in a 0.9% NaCl, 0.4% EtOH vehicle) by intraperitoneal (i.p.) injection at the indicated time intervals prior to tissue collection at necropsy. This in vivo dose level of E2 has been shown to induce changes in uterine wet weight, tissue architecture, and gene expression characteristic of estrogen receptor activation. For all other experiments, animals are i.p. administered a single 40 μg/kg bolus of E2 4 h prior to tissue harvest, while control animals receive vehicle only in all studies. Batimastat is administered i.p. at a dose level (40 mg/kg in a 1× PBS, 0.1% Tween-20 vehicle) shown to be effective at inhibiting MMPs in vivo 4 h prior to E2 or saline control.

References:

[1]. Yin Z, et al. Increased MMPs expression and decreased contraction in the rat myometrium during pregnancy and in response to prolonged stretch and sex hormones. Am J Physiol Endocrinol Metab. 2012 Jul 1;303(1):E55-70.
[2]. Botos I, et al. Batimastat, a potent matrix mealloproteinase inhibitor, exhibits an unexpected mode of binding. Proc Natl Acad Sci U S A. 1996 Apr 2;93(7):2749-54.
[3]. Hansen HP, et al. Inhibition of metalloproteinases enhances the internalization of anti-CD30 antibody Ki-3 and the cytotoxic activity of Ki-3 immunotoxin. Int J Cancer. 2002 Mar 10;98(2):210-5.
[4]. Giavazzi R, et al. Batimastat, a synthetic inhibitor of matrix metalloproteinases, potentiates the antitumor activity of cisplatin in ovarian carcinoma xenografts. Clin Cancer Res. 1998 Apr;4(4):985-92.
[5]. Ricci S, et al. Inhibition of matrix metalloproteinases attenuates brain damage in experimental meningococcal meningitis. BMC Infect Dis. 2014 Dec 31;14:726.
[6]. Russo LA, et al. Regulated expression of matrix metalloproteinases, inflammatory mediators, and endometrial matrix remodeling by 17beta-estradiol in the immature rat uterus. Reprod Biol Endocrinol. 2009 Nov 4;7:124.

产品文档 Product Documents

化学性质Chemical Properties

CAS 号
130464-84-5
同义词
(2S,3R)-N-羟基-N'-[(2S)-1-甲基氨基-1-氧代-3-苯基丙-2-基]-3-异丁基-2-(噻吩-2-基硫甲基)丁二酰胺单钠盐,BB-94 sodium salt
SMILES
[O-]NC([C@@H](CSC1=CC=CS1)[C@@H](CC(C)C)C(N[C@@H](CC2=CC=CC=C2)C(NC)=O)=O)=O.[Na+]
分子式
C23H30N3NaO4S2
分子量
499.62 g/mol
溶解性
Soluble in DMSO
保存条件
Store at -20°C
General tips
请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。
储备液的保存方式和期限:-80°C 储存时,请在 6 个月内使用,-20°C 储存时,请在 1 个月内使用。
为了提高溶解度,请将管子加热至 37°C,然后在超声波浴中震荡一段时间。
Shipping Condition
评估样品解决方案:配备蓝冰进行发货。所有其他可用尺寸:配备 RT,或根据请求配备蓝冰。

计算工具摩尔浓度 / 稀释 / 分子量 / 单位换算 / 体内配方 / 溶解度

g/mol